Sanctuary Advisors LLC Acquires New Stake in Exelixis, Inc. (NASDAQ:EXEL)

Sanctuary Advisors LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 27,504 shares of the biotechnology company’s stock, valued at approximately $652,000.

Several other institutional investors also recently bought and sold shares of EXEL. Fisher Asset Management LLC grew its stake in shares of Exelixis by 232.6% in the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 728 shares in the last quarter. Rise Advisors LLC bought a new stake in shares of Exelixis during the first quarter valued at approximately $28,000. Park Place Capital Corp bought a new position in shares of Exelixis in the second quarter worth $45,000. GAMMA Investing LLC raised its position in shares of Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,041 shares in the last quarter. Finally, EntryPoint Capital LLC lifted its position in Exelixis by 537.2% in the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,746 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research report on Wednesday, September 18th. Truist Financial reaffirmed a “buy” rating and set a $33.00 price objective (up from $32.00) on shares of Exelixis in a report on Thursday, August 8th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. JMP Securities reiterated a “market outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Friday. Finally, Oppenheimer reissued an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Tuesday, July 30th. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and an average target price of $28.15.

Insider Activity at Exelixis

In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $27.19, for a total value of $3,398,750.00. Following the completion of the transaction, the chief financial officer now directly owns 721,680 shares in the company, valued at approximately $19,622,479.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the sale, the chief financial officer now owns 721,680 shares of the company’s stock, valued at approximately $19,622,479.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the transaction, the executive vice president now directly owns 605,325 shares in the company, valued at $15,968,473.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 327,858 shares of company stock valued at $8,640,129 over the last three months. 2.85% of the stock is owned by insiders.

Exelixis Stock Up 0.0 %

Shares of Exelixis stock opened at $26.24 on Tuesday. The stock has a market capitalization of $7.96 billion, a price-to-earnings ratio of 41.00, a price-to-earnings-growth ratio of 0.54 and a beta of 0.54. Exelixis, Inc. has a twelve month low of $18.64 and a twelve month high of $27.83. The company has a 50-day simple moving average of $26.19 and a two-hundred day simple moving average of $23.68.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The business had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million. On average, sell-side analysts anticipate that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.